New chemotherapy options for the treatment of malignant gliomas
- 1 May 1999
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 11 (3) , 157-61
- https://doi.org/10.1097/00001622-199905000-00003
Abstract
Chemotherapy remains part of the treatment triad that includes surgery and radiation therapy for the management of malignant gliomas. In recent years there has been an increased understanding of the molecular pathways of malignant transformation. Based on this research, new drugs have been evaluated, with specific cellular targets in mind that can be modified or inhibited. Many of these agents are now being tested in phase I and II clinical trials and have shown some promising results. Clearly, not all patients with malignant gliomas respond equally to chemotherapy. Recent evidence suggests that certain molecular markers may predict chemosensitivity in some tumor types, particularly anaplastic oligodendroglioma. This article reviews recent trends in the use of chemotherapy and clinical trials of new therapies for adults with malignant gliomas.Keywords
This publication has 17 references indexed in Scilit:
- DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.Journal of Clinical Oncology, 1998
- A Phase I-II Trial of Lovastatin for Anaplastic Astrocytoma and Glioblastoma MultiformeAmerican Journal of Clinical Oncology, 1998
- Matrix metalloproteinase inhibitors in the treatment of cancerMedical Oncology, 1997
- Matrix metalloproteinase inhibitorsInvestigational New Drugs, 1997
- Signal transduction pathways and their relevance in human astrocytomasJournal of Neuro-Oncology, 1997
- Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1994
- Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adultsCancer, 1993
- Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumoursEuropean Journal Of Cancer, 1993
- Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)British Journal of Cancer, 1992
- Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarrazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final reportInternational Journal of Radiation Oncology*Biology*Physics, 1990